Exchange: NASDAQ·Updated 07:30 PM EST

IMUX News

News
all
press releases
Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatePR NewswireNEW YORK, Nov. 13, 2026 Pivotal Phase 3 ENSURE-1 and ENSURE-2 Trials of Vidofludimus Calcium in Relapsing...
PR Newswire
Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate UpdatePR NewswireNEW YORK, Nov. 13, 2026 Pivotal Phase 3 ENSURE-1 and ENSURE-2 Trials of Vidofludimus Calcium in Relapsing...
PR Newswire
More News
Immunic to Participate in Investor Conferences in November Immunic to Participate in Investor Conferences in NovemberPR NewswireNEW YORK, Nov. 2, 2026 NEW YORK, Nov. 2, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX),a late-stage biotechnology company pioneering the development of novel oral...
PR Newswire
Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026 Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026PR NewswireNEW YORK, Oct. 29, 2026 NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX),a late-stage biotechnology...
PR Newswire
BBCP, UCB, TGS, STX and IMUX have been added to the Zacks Rank #1 (Strong Buy) List on October 22, 2026.
Zacks
Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at...
PR Newswire
(RTTNews) - On Monday, Immunic, Inc. (IMUX), a biotechnology company developing oral treatments for neurological diseases, appointed Jaa Roberson as Chief People Officer, effective immediately. She will report to CEO Erik Lundgren and join the executive leadership team...
Nasdaq News: Markets
Immunic Appoints Jaa Roberson as Chief People Officer Immunic Appoints Jaa Roberson as Chief People OfficerPR NewswireNEW YORK, Oct. 19, 2026 Appointment Supports Immunic's Strategy to Build a Leading Multiple Sclerosis Organization Ahead of Potential Transition to Fully Integrated Commercial...
PR Newswire
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS MeetingPR...
PR Newswire
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 PR Newswire NEW YORK, Sept. 2, 2026 NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX),a late-stage biotechnology...
PR Newswire
Immunic Appoints Chitrang Dav as Chief Data and Digital Officer Immunic Appoints Chitrang Dav as Chief Data and Digital Officer PR Newswire NEW YORK, Sept. 1, 2026 New C-Suite Role and Appointment Underscore Commitment to Building a Strong, Commercial-Ready Data Ecosystem, in Preparation for...
PR Newswire

Advertisement|Remove ads.